Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins.

Abstract

Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.

• Authors: Lia M Haynes, Congrong Miao, Jennifer L Harcourt, Joel M Montgomery, Mai Quynh Le, Sergey A Dryga, Kurt I Kamrud, Bryan Rivers, Gregory J Babcock, Jennifer Betts Oliver, James A Comer, Mary Reynolds, Timothy M Uyeki, Daniel Bausch, Thomas Ksiazek, William Thomas, Harold Alterson, Jonathan Smith, Donna M Ambrosino, Larry J Anderson
• Journal: Clinical and vaccine immunology : CVI (Clin Vaccine Immunol) Vol. 14 Issue 3 Pg. 331-3 (Mar 2007) ISSN: 1556-6811 [Print] United States
• PMID: 17229882 (Publication Type: Journal Article)

Chemical References

• Antibodies, Viral
• Coronavirus Nucleocapsid Proteins
• Membrane Glycoproteins
• Nucleocapsid Proteins
• Recombinant Proteins
• Spike Glycoprotein, Coronavirus
• Viral Envelope Proteins
• spike glycoprotein, SARS-CoV

Topics

• Antibodies, Viral (blood)
• Coronavirus Nucleocapsid Proteins
• Enzyme-Linked Immunosorbent Assay
• Humans
• Membrane Glycoproteins (immunology)
• Nucleocapsid Proteins (immunology)
• Recombinant Proteins (immunology)
• Severe acute respiratory syndrome-related coronavirus (immunology)
• Sensitivity and Specificity
• Serologic Tests
• Severe Acute Respiratory Syndrome (diagnosis)
• Spike Glycoprotein, Coronavirus
• Viral Envelope Proteins (immunology)